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Abstract
Background: Nearly one in three Americans are financially burdened by their medical expenses. To mitigate
financial distress, experts recommend routine physician-patient cost conversations. However, the content and
incidence of these conversations are unclear, and rigorous definitions are lacking. We sought to develop a novel set
of cost conversation definitions, and determine the impact of definitional variation on cost conversation incidence
in three clinical settings.
Methods: Retrospective, mixed-methods analysis of transcribed dialogue from 1,755 outpatient encounters for
routine clinical management of breast cancer, rheumatoid arthritis, and depression, occurring between 2010–2014.
We developed cost conversation definitions using summative content analysis. Transcripts were evaluated
independently by at least two members of our multi-disciplinary team to determine cost conversation incidence
using each definition. Incidence estimates were compared using Pearson’s Chi-Square Tests.
Results: Three cost conversation definitions emerged from our analysis: (a) Out-of-Pocket (OoP) Cost – discussion
of the patient’s OoP costs for a healthcare service; (b) Cost/Coverage – discussion of the patient’s OoP costs or
insurance coverage; (c) Cost of Illness– discussion of financial costs or insurance coverage related to health or
healthcare. These definitions were hierarchical; OoP Cost was a subset of Cost/Coverage, which was a subset of
Cost of Illness. In each clinical setting, we observed significant variation in the incidence of cost conversations
when using different definitions; breast oncology: 16, 22, 24 % of clinic visits contained cost conversation (OOP
Cost, Cost/Coverage, Cost of Illness, respectively; P < 0.001); depression: 30, 38, 43 %, (P < 0.001); and rheumatoid
arthritis, 26, 33, 35 %, (P < 0.001).
Conclusions: The estimated incidence of physician-patient cost conversation varied significantly depending on the
definition used. Our findings and proposed definitions may assist in retrospective interpretation and prospective
design of investigations on this topic.
Keywords: Cost of illness, Health expenditures, Out-of-pocket costs, Patient-physician communication,
Medical decision-making, Patient-centered care
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Background
Despite recent reductions in national healthcare expen-
ditures, nearly 1 in 3 Americans are financially burdened
by their medical expenses [1, 2]. Beyond just financial
consequences, high out-of-pocket medical costs have
been associated with lower quality of life, delayed or for-
gone care, and increased risk of adverse health outcomes
[2–7]. Our group and others have recommended that
physicians and patients engage in routine discussions
about healthcare costs during clinic visits, in order to
help patients avoid unnecessary out-of-pocket expendi-
tures [8–12]. Theoretically, such discussions could allow
physicians and patients to weigh medical and financial
trade-offs of treatment or diagnostic options, making
choices that optimize patients’ health outcomes while
minimizing avoidable financial distress.
Despite these calls to action, there remains a paucity of
data informing current understanding of physician-patient
cost communication [12]. Little is known about the con-
tent of cost conversations and their incidence is unclear,
with widely varying estimates in the published literature.
In fact, incidence estimates range from 14–15 % of pa-
tients ever discussing cost with their physicians [13, 14],
to 44–65 % discussing it with their physicians in the previ-
ous year alone [15, 16]. This heterogeneity is likely due to
a combination of factors, including but not limited to:
clinical context, socioeconomic status of the patient popu-
lation, and mode of inquiry (e.g. physician survey, patient
survey, analysis of recorded clinical encounters).
Additionally, differences in ‘cost conversation’ defin-
ition or criteria may also contribute to the observed vari-
ation in cost conversation incidence estimates. In this
paper, we first provide a critical review of cost conversa-
tion definitions used in prior studies, highlighting the
need for more rigorous definitions. We then describe
our development of novel cost conversation definitions
through mixed-methods analysis of 1,755 outpatient
encounters for routine clinical management of three dif-
ferent diseases (breast cancer, rheumatoid arthritis, and
depression). Finally, we report the cost conversation in-
cidence in our sample using each definition, to evaluate
the impact of definitional variation on cost conversation
incidence estimates. In doing so, we provide clarifying
insights for retrospective interpretation of existing litera-
ture and future investigation on this important aspect of
patient experience [1, 11, 17].
Methods
Sample description
Visit transcripts were sampled from the Verilogue Point-
of-Practice™ database of audio-recorded clinical encoun-
ters (http://www.verilogue.com). Details about the sample
have been published elsewhere [18]. Briefly, physicians
were recruited randomly by Verilogue from available lists
and paid to record routine clinic visits with their patients.
Physicians recruited patients sequentially and obtained
consent prior to the recorded visit using a double opt-in
method. Patients were not compensated for their partici-
pation. Physicians and patients were unaware of specific
research questions for which their recorded visits would
be used.
We obtained from Verilogue full visit transcripts from
the most recent 1,000 encounters for management of
breast cancer, major depressive disorder, and rheumatoid
arthritis. These particular disease states were chosen be-
cause they are prevalent, can be managed with diagnos-
tic and therapeutic options varying widely in cost, and
feature the different clinical contexts of a potentially life-
threatening disease, a mental illness, and a chronic, de-
bilitating disease. We excluded visits with non-physician
providers, those occurring outside of the United States,
and those that included only physician dictations or dis-
cussions of axial spondyloarthropathy (instead of rheuma-
toid arthritis).
All protected health information was removed during
the transcription process. The Duke University Institu-
tional Review Board approved this study.
Surveying extant cost conversation definitions
As a preliminary step in cost conversation definition
development, we performed a literature review to
identify existing definitions and criteria. We searched
for English language articles published in PubMed,
EMbase, Cochrane Database, and the Social Science
Research Network using terms synonymous with ‘out-
of-pocket costs’ or ‘cost discussion’. We reviewed ti-
tles and abstracts from resultant articles, retaining
those that addressed physician-patient communication
about healthcare costs. We further investigated all
pertinent references in those articles to find additional
studies not included in the above databases. In line with
our overarching research aims, we focused our analysis on
investigations reporting estimates of cost conversation
incidence in U.S.-based study populations. We identified
19 studies meeting these criteria, and have described their
study populations, clinical settings, cost conversation
definitions, and incidence estimates in Table 1. Notably,
there have been additional studies of physician-patient
communication that did not report incidence estimates,
but surveyed patient and/or physician attitudes about
cost conversation [19–22], recommended communication
strategies for cost conversation [8, 23, 24], and provided
clinical and ethical perspectives on the topic [10, 11, 25].
Although these articles provided helpful context for the
present investigation, they did not feature cost conversa-
tion definitions different from those detailed in Table 1.
Further discussion of their content is beyond the scope of
the present review.
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Table 1 Published estimates of physician-patient cost conversation incidence with accompanying definitions
First author, year, (N) Clinical setting and population characteristics Cost conversation definition or criteria Estimated cost conversation incidence
Analyses of recorded dialogue from clinic visits
Hunter, 2016 [18] N = 1,755 Outpatient visits taking place in community-based
practices nationwide from 2010–2014 for routine
management of breast cancer, rheumatoid arthritis,
and major depressive disorder. Encounters featured
specialist physicians and patients >18 years old.
• Any mention of the patient’s financial
costs or insurance coverage related to
a specific intervention.
Overall, 30 % of clinic visits contained cost
conversation. Cost conversations were observed
in 22 % of breast oncology visits, 33 % of
rheumatoid arthritis visits, and 38 % of
depression visits.
Tarn, 2013 [38] N = 1,477 Outpatient visits with primary care providers occurring
in a variety of locations around the U.S. from 1998–2010.
• Discussion of themes concerning cost
and/or affordability discussed.
Cost and/or affordability was mentioned for 4.2 %
of dietary supplements discussed.
Beard, 2010 [33] N = 200 Rheumatoid arthritis patients visiting rheumatologists
from 2003–2005 as part of randomized controlled trial
to improve communication about quality of life and
medication concerns in rheumatology visits.
• Discussion of medication-related costs;
could be ‘explicit’ (e.g. price of intervention)
or ‘implicit’ (e.g. copay assistance, insurance
coverage).
34 % of visits included discussion of medication-
related costs.
Tarn, 2006 [32] N = 185 Outpatient visits to family physicians, internists, and
cardiologists as part of the Physician Patient
Communication Project (1999).
• Discussion of themes concerning
medication cost and insurance.
15 % of visits with newly prescribed medications
contained discussion of cost or insurance coverage.
Survey studies in non-subspecialty settings
Alexander, 2003 [13] N = 484 General internists and their patients residing in the
Greater Chicago area.
• Discussion of out-of-pocket (OoP) costs. 15 % of patients discussed OoP costs with their
physicians.
35 % of physicians discussed OoP costs with
these patients.
Piette, 2004 [16] N = 660 Elderly adults with chronic illnesses who reported
underusing medication in the prior year because
of cost.
• Any conversation about problems paying
for prescription medications.
65 % of patients with cost-related medication
underuse discussed the cost problem with their
physician in the prior year.
Shrank, 2006 [30] N = 509 Random sample of physician members of the California
Medical Association. Participating physicians practiced
in a variety of primary care and specialty settings.
• Discussion of OoP costs (defined as what
the patient pays) or total costs with patients.
15 % of physicians reported discussing OoP costs
most or all the time; 5 % reported total costs most
or all the time. 45 % reported discussing OoP cost
seldom or never.
Shrank, 2006 [44] N = 1707 Nationwide sample of patients managed by family
medicine or general practitioners.
• Discussion of OoP costs. 33 % of patients with incentive-based pharmacy
benefit designs discussed OoP costs with their
physicians.
Wilson, 2007 [39] N = 17,569 Nationwide sample of Medicare beneficiaries aged
65 years or older.
• Talking with any doctor about the cost of
prescription medicines in the previous
12 months.
Overall, 31 % of seniors talked with at least one of
their physicians about medication costs. 61 % of
those reporting cost-related non-adherence
discussed cost with at least one of their physicians.
Beran, 2007 [31] N = 678 Internal medicine and family physicians caring for
senior patients, practicing clinical medicine, and
residing in California.
• Discussion of OoP cost of medications. 43 % of physicians reported discussing medication
costs with at least half of their senior patients in
the previous 30 days.
Tseng, 2007 [47] N = 1,116 Seniors enrolled in a Medicare managed care plan,
surveyed in 2002. Half exceeded caps on their drug
benefits the previous year, and all had total drug
expenditures in the top quartile of members in their
cap level.
• ‘Has your provider ever asked you whether
you can afford the cost of your medications?
Overall, 17 % said providers asked about affordability;
19 % said providers usually or always discussed prices
when he or she writes a prescription.
• “How often do you and your provider talk
about the price of a medication when he or















Table 1 Published estimates of physician-patient cost conversation incidence with accompanying definitions (Continued)
Tseng, 2010 [28] N = 5,085 Patients with diabetes mellitus enrolled in multi-center
study of diabetes care in managed care settings.
• Discussion of medication costs. 19 % of patients who reported being open to
discussing cost trade-offs (discussing lower cost
drugs with higher chance of adverse effects, lower
effectiveness, or higher dosing frequency) said their
physician usually or always discussed drug costs
when prescribing.
Schmittdiel, 2010 [15] N = 1,458 Patients with diabetes mellitus enrolled in multi-center
study of diabetes care in managed care settings.
• Talking about the amount paid for
prescription drugs during 2006.
44 % of patients discussed prescription drug costs
with any doctor during 2006.
Survey studies in subspecialty settings
Schrag, 2007 [27] N = 167 Random, nationwide sample of medical oncologists
practicing in the U.S.
• Discussion of the costs of cancer
treatment.
42 % of oncologists reported discussing cost always
or most of the time, 32 % reported sometimes
discussing cost with their patients.
Patel, 2009 [45] N = 343 Random, nationwide sample of pediatricians and family
physicians who care for children with asthma in the U.S.
• Asking the child’s family about OoP costs
a newly prescribed asthma medication.
50 % of physicians reported asking about cost
regularly when prescribing new asthma medications
for children.
Neumann, 2010 [26] N = 787 Random sample of U.S. based oncologists with an
oversample from California.
• Discussion of cancer treatment costs. 43 % always or frequently discussed cancer treatment
costs with their patients, while 37 % said they did so
occasionally.
Irwin, 2014 [14] N = 134 Breast cancer patients at a single academic cancer
center.
• Discussion of costs of care. 14 % discussed costs with their doctor.
Patel, 2014 [46] N = 422 African-American adult women with persistent asthma
recruited from a single academic center.
• Did you talk with your doctor about out-
of-pocket healthcare costs?
39 % have discussed costs with their doctors.
Bestvina, 2014 [29] N = 300 Cancer patients in quaternary referral cancer center and
affiliated rural oncology practices.
• Discussion of OoP costs of cancer care
with oncologist.
19 % discussed the cost of cancer care with their
oncologists.
We searched PubMed, EMbase, Cochrane Database, and the Social Science Research Network using terms synonymous with ‘out-of-pocket costs’ and ‘cost discussion’. We reviewed titles and abstracts from resultant
articles, retaining those that reported on the frequency of physician-patient communication about healthcare costs. We further investigated all pertinent references in these articles to identify additional studies not
















As seen in Table 1, substantial heterogeneity in cost
conversation definitions were observed throughout stud-
ies reporting incidence estimates. For example, some
studies asked participants whether they discussed cost of
medications or treatment, but gave no definition or cri-
teria to help inform them about what it meant to discuss
cost [14, 26–28]. Other studies specifically asked about
‘out-of-pocket’ costs, but did not define the concept fur-
ther [13, 29-31]. Some studies queried about discussion
of patient costs [15, 16], while others did not specify
whose cost was of interest [14]. Four prior studies per-
formed mixed-methods analysis of cost conversation dia-
logue and provided examples of cost conversations; [18,
32, 33, 38] however, their analytic foci were not the cost
conversation definitions themselves, and thus omitted de-
tailed discussion of their genesis and nuance. Accordingly,
we sought to develop novel, rigorous cost conversation
definitions for our own analyses [18].
Qualitative content analysis
Though review of the cost conversation literature failed
to produce a guiding theoretical framework for our ana-
lysis, examples from prior work in combination with our
collective experience in healthcare and healthcare analyt-
ics provided a starting point for our study. Keywords
such as ‘cost’, ‘money’, ‘expense’, ‘insurance’, etc. served
as indicators of a potential cost discussion, but could not
be used to exclusively or conclusively identify a cost
conversation. For these reasons, we approached the
qualitative portion of our mixed-method study using an
inductive application of summative content analysis [34].
Our method was summative in that it relied on a base
understanding of how cost might be discussed and pro-
ceeded with the intent to quantify observations of such
instances. However, it was still inductive in that our cost
definitions were created through iterative passes through
the data described in phases 1–3 below.
To mitigate bias and maximize the breadth and depth of
cost conversation analysis, a multi-disciplinary group was
involved in this process: physicians with extensive clinical
and research experience (S.Y.Z., P.A.U.), medical students
(W.G.H., A.H., C.Z.Z.), trained conversation analysts
(J.K.D, L.D.W., A.H.), undergraduate students (A.W.,
O.C.), and graduate students training in public policy
(C.C., R.F.) and marketing (D.B.). By incorporating individ-
uals with diverse backgrounds in all phases of the analysis,
we enhanced both the recognition and interpretation of
cost conversations, creating an environment in which clini-
cians, social scientists, and policy specialists contributed
equally in the multiple rounds of data-driven discussion.
Phase 1: immersion in the data
The foundational first step in cost conversation defin-
ition development involved immersion in the data [35].
Through close reading, we obtained a general understand-
ing of cost conversations in their entirety, and allowed
relevant themes and phenomena to emerge from the text.
Themes, phenomena, and general observations were
discussed in group settings and collected for subsequent
definition development. Approximately 100 transcripts
containing one or more keywords related to finances (e.g.
expensive, cheap, insurance, dollars, co-pay, Medicare,
deductible, costly, etc.) were used in this phase.
Phase 2: definition development
Based on phase 1 observations, clinical experience, and
research experience, an initial set of definitions was cre-
ated to classify relevant cost conversation types. Using
analytic induction, we adjusted, merged, and split defini-
tions until they represented distinct cost conversation
types. Final definitions with accompanying examples are
described in results text and shown in Fig. 1.
Phase 3: definition implementation
To reduce individual coder bias and improve accuracy,
encounters were analyzed independently by at least two
team members of our multidisciplinary team (J.K.D.,
C.K, L.D.W., C.Z.Z., W.G.H., P.A.U., A.W., C.C., R.F.,
T.T.) to determine presence or absence of cost conversa-
tions using each of the final definitions. All decisions
were assessed for agreement; in cases of agreement, the
corresponding decision was assigned as ‘final’. When
discrepant, the final decision was made by group con-
sensus. Team members with clinical experience (P.A.U.,
W.G.H.) supervised discrepancy resolution to ensure
proper interpretation of clinical matters. All coding was
applied using NVivo software (QSR International Pty
Ltd. Version 10, 2014).
Statistical analysis
With one recording per patient, the unit of measurement
was the singular visit. Ninety-five percent confidence in-
tervals for all proportions were calculated using Clopper
and Pearson’s exact method [36]. Pearson’s Chi-Square
test was used to compare cost conversation incidence esti-
mates. R software (R Core Team (2013), Version 3.0.1,
http://www.R-project.org/) was used to perform all statis-
tical analyses. All authors had full access to the data, and
take responsibility for its integrity.
Results
Study population
Patient, physician, and visit characteristics are presented
in Table 2 and described in detail elsewhere [18]. A total
of 118 unique physicians comprised of N = 56 oncolo-
gists, N = 36 psychiatrists, and N = 26 rheumatologists
recorded visits for this study. The median number of
visits recorded by each physician was 12 (interquartile
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range (IQR), 4 to 22). Notable differences between clin-
ical settings included a higher percentage of male physi-
cians in major depression visits (100 %), higher median
number of visits recorded by each rheumatologist (28;
IQR 5–41), and higher percentage of female patients in
the breast oncology setting (99 %). For detailed informa-
tion about clinic visit locations, see Additional file 1:
Table S1.
Three definitions of ‘cost conversation’
Three definitions of cost conversation emerged from
our analysis. These definitions were hierarchical; all
dialogue considered cost conversation using the nar-
rowest definition (addressing the patient’s out-of-
pocket healthcare costs; OoP cost), was also consid-
ered cost conversation using the broader definition
(addressing patient’s out-of-pocket costs or insurance
coverage; Cost/Coverage). Dialogue counted as cost
conversation by the OoP Cost or Cost/Coverage defi-
nitions was also considered cost conversation using
the broadest definition (conversations about financial
costs or insurance coverage broadly related to health
or healthcare; Cost of Illness). These definitions are
described in more detail below with illustrative examples
in the text and in Fig. 1.
OoP cost: conversation about the patient’s out-of-pocket
costs
The OoP Cost definition constrained the concept of cost
conversation to discussions about the patient’s out-of-
pocket costs for past, present, or potential healthcare
services. In alignment with the Agency for Healthcare
Research and Quality (AHRQ), out-of-pocket costs were
defined as the portion of total healthcare expenses paid
by the patient (not including payments made for health
insurance premiums) [37]. In contrast to some prior
studies, we had no a priori emphasis on cost conversa-
tions related to particular types of interventions, (e.g.
prescription medications, dietary supplements, domain-
specific treatments such as chemotherapy related costs);
[15, 29, 38] thus, we included conversations addressing
the patient’s out-of-pocket costs for any healthcare
service. Specifically, healthcare services were defined
as any diagnostic or therapeutic modality intended to
assess or alter a patient’s disease course or health-
related quality of life. Accordingly, we included
Fig. 1 Three cost conversation definitions with explanations and example quotes
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discussions of patient out-of-pocket costs for a variety
of interventions, including, but not limited to: phar-
macotherapies (e.g. prescription medications, over-
the-counter medications such as non-steroidal anti-
inflammatory agents, fish oil, folic acid, vitamin D);
diagnostic tests (e.g. CT scan, complete blood count,
OncoType DX, BRCA testing); services from non-
physician healthcare providers (e.g. dental care, wound
management, cognitive behavioral therapy, podiatric care);
and additional therapies such as acupuncture, nutritional
supplements, or massage, when provided for medical but
not recreational purposes (e.g. acupuncture for treatment
of chronic pain, nutritional supplement for cachexia or
malnutrition).
We observed a few common forms of dialogue meet-
ing the OoP Cost definition. The clearest form of OoP
Cost conversation was when the patient’s out-of-pocket
costs were explicitly discussed (e.g. Dr: “How much
copay do you have for that?”), or described with an exact
dollar value (e.g. Dr: “With Methotrexate, you’re looking
at about $20 per month”). Another common form of
OoP Cost conversation occurred when one of the parties
described the patient’s out-of-pocket costs with a subject-
ive description (e.g. Dr: “Do you want to take biologics? Pt:
“I don't have very good insurance. I have to pay 50 % and
it costs a lot.”).
In some cases, costs were discussed without any expli-
cit textual evidence indicating whether they were specif-
ically the patient’s out-of-pocket costs, as opposed to the
costs born by other stakeholders, such as insurance
companies or the healthcare system as a whole. Rather
than exclude all such dialogue without explicit literal
cues (e.g. Pt: “Can we do the 3 month supply of that?
It’s cheaper that way.”), we carefully evaluated the
context of the dialogue to determine its implicit
meaning. For example, in the latter quote, the patient
does not explicitly state for whom the 3-month sup-
ply will be cheaper; however, she made no other com-
ments about insurance companies or the healthcare
system as a whole throughout the visit. In the ab-
sence of any evidence suggesting that the patient was
considering other stakeholders’ costs, we inferred that
she was discussing her own out-of-pocket costs (i.e. it’s
cheaper that way [for me]).
Another common form of dialogue meeting the
OoP Cost definition was discussion of strategies by
which the patient’s out-of-pocket costs could be re-
duced. These discussions did not always contain ex-
plicit textual references to the patient’s out-of-pocket
costs (e.g. Dr: “We’ll get you set up with the copay as-
sistance program for Xeloda before you leave today.”);
however, they were still considered OoP Cost conver-
sations based on the notion that discussion of cost-
reducing strategies for the patient constitute indirect,
implied discussion of their out-of-pocket costs. For ex-
ample, in the latter quote, by offering to ‘set [the patient]
up with the copay assistance program’, the physician was
Table 2 Physician, patient, and visit characteristicsa
Characteristics Breast cancer Depression Rheumatoid
arthritis
Patients (N) 677 422 656
Age, years (%)
19–34 1 23 5
35–54 28 44 29
55–74 54 33 53
75+ 17 1 13
Gender, female (%) 99 66 78
Race (%)
Caucasian 71 83 75
African– American 19 7 11
Hispanic 6 5 9
Other 4 4 5
Insurance status (%)
Private 49 49 54
Public 51 43 41
Uninsured 0 8 4
Physicians (N) 56 36 26
Visits recorded,
median (N), (IQR)
9 (5–19) 13 (4–17) 28 (5–41)
Gender, male (%) 89 100 81
Years in practice (%)
0–10 37 16 11
11–20 44 34 58
21–30 15 44 14
31+ 4 6 16






Visit Locations by US
regionb (N)
East North Central 98 105 47
East South Central 23 21 69
Middle Atlantic 56 85 100
Mountain 80 22 0
New England 41 39 20
Pacific 74 18 177
South Atlantic 222 41 50
West North Central 23 55 102
West South Central 60 36 91
aValues are percentages of total non–missing observations unless otherwise
indicated. Less than 1 % of observations are missing. Percentage totals do not
all sum to 100 due to rounding
bList of states comprising each United States geographic region is provided in
the Additional file 1: Table S1. Abbreviation: IQR indicates inter–quartile range
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implicitly stating that he would attempt to lower the pa-
tient’s out-of-pocket costs for Xeloda. See Fig. 1 for more
examples.
Cost/coverage: conversation addressing patients’ out-of-
pocket costs OR insurance coverage
As depicted in Fig. 1, dialogue considered cost conversa-
tion using the OoP Cost definition was also considered
cost conversation using the Cost/Coverage definition.
The Cost/Coverage definition broadens the concept of
‘cost conversation’ beyond the OoP Cost definition by
also including discussions about insurance coverage (e.g.
Pt: “Do you think that we’ll be able to get the Enbrel cov-
ered?”). We observed a few common forms of dialogue
addressing insurance coverage throughout our sample:
1) discussion of presence or absence of insurance cover-
age for interventions previously ordered (e.g. Dr: “Has
your insurance been covering the Abilify?”) or interven-
tions under consideration which the patient had never
been prescribed (e.g. Dr: “I’m going to talk to [my staff]
and see if we can actually get this [Faslodex] approved
by your insurance, today or tonight.”); and 2) discussion
about the perceived quality or degree of coverage (e.g.
Dr: “So you have pretty good insurance through
Piedmont?”).
Importantly, discussions about insurance coverage in-
cluded in the Cost/Coverage definition were required to
be related to a particular healthcare service received by
the patient (Dr: “We can do the paperwork so that the
insurance company approves [the lab studies] before we
do them… You have insurance, right?” Pt: “Yeah.”). By
contrast, discussion of insurance coverage that was not
tied to a specific intervention (e.g. physician queries
about patients’ insurance status occurring at the begin-
ning of clinic visits as part of routine demographic data
collection) was not included as cost conversation using
the Cost/Coverage definition.
Cost of illness: conversation about financial costs or
insurance coverage broadly related to health or healthcare
Dialogue considered cost conversation using the OoP
Cost or Cost/Coverage definitions was also included as
cost conversation using the Cost of Illness definition. Add-
itionally, though, the Cost of Illness definition broadened
the concept of cost conversation in a few important ways.
First, the Cost of Illness definition included discussions of
healthcare costs born by any stakeholder (not just the pa-
tient). Thus, discussions of healthcare costs born by family
members, friends, or society as a whole were considered
cost conversations using this definition (e.g. Dr: The FDA
pulled Avastin because it's an expensive drug, a very ex-
pensive drug. Thousands and thousands per month, and if
no one’s living longer, what’s the point of our health care
system spending all the money on it?”).
Second, the Cost of Illness definition broadened the
concept of cost conversation by including discussions of
insurance coverage that were not related to a specific
intervention, as in the aforementioned physician queries
about insurance status occurring at the beginning of
some clinic visits (e.g. Dr: “You live with your daughter?
And you are Hispanic? You’re on Medicaid?”). These
queries were often brief, and resultant information was
not pursued further to assess or manage the patient’s
healthcare costs. This inclusion reflects and implements
the perspective that any discussion of insurance cover-
age, no matter the context, addresses the patient’s costs.
Lastly, the Cost of Illness definition broadened the
concept of cost conversation by also including those dis-
cussions in which the physician and patient addressed
secondary financial consequences of missing work due
to treatment side effects. For example, some breast can-
cer patients complained their chemotherapy was causing
them either to lose wages or become at risk for termin-
ation and loss of health insurance coverage. Since these
situations did not address the costs the patient would
pay for a health care intervention, they did not meet the
criteria for the OOP Cost or Cost/Coverage definitions;
however, they did address financial costs related to the
patient’s health problems, and were thus included in the
Cost of Illness definition.
Excluded from all definitions
We excluded several types of conversation from all three
definitions: discussions of non-healthcare related costs
(e.g. children’s college tuition), general financial issues not
explicitly mentioned to be impacting the patient’s ability
to access or afford medical care (e.g. receiving a pay cut),
or the logistics of obtaining an intervention (e.g. recom-
mending a specific pharmacy to fill without mentioning
any corresponding cost savings).
Incidence of cost conversations
Published estimates of cost conversation incidence
Our review demonstrated that estimates of cost conver-
sation incidence vary widely in the published literature
(Table 1). Incidence estimates range from 14–19 % of
oncology patients ever discussing healthcare costs with
physicians [14, 29], to 44 % of diabetic patients discuss-
ing prescription drug costs with their physicians in the
previous year [15], to 65 % of patients with cost-related
non-adherence discussing healthcare costs with physi-
cians in the previous year [16]. Despite marked hetero-
geneity with respect to study methodology, patient
characteristics, and time frame of data collection, a few
notable patterns emerged.
One such pattern is significant variation in cost conver-
sation incidence across clinical settings. This was demon-
strated in a prior investigation by our group, in which a
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statistically significant difference in cost conversation inci-
dence was observed across three clinical settings, breast
oncology (estimated cost conversation incidence, 22 % of
clinic visits), rheumatoid arthritis (33 % of visits), and de-
pression (38 % of visits; analysis of variance P < 0.001 for
comparison among the three settings) [18]. Interestingly,
our estimate of cost conversation incidence in the setting
of rheumatoid arthritis was nearly equal to the estimate
reported by Beard et al. (33 % vs. 34 % of visits, respect-
ively), which was also produced by analysis of recorded
dialogue [33]. These estimates from rheumatoid arth-
ritis settings were generally greater than estimates from
oncology settings, in which fewer than 20 % of patients
reported discussing cost with their oncologists [14, 29].
Another pattern emerging in the published literature
was that cost conversation incidence estimates based on
physician surveys were generally higher than those based
on patient surveys; this was best demonstrated in a study
performed by Alexander and colleagues, in which 15 % of
patients reported ever discussing cost with their providers,
but 35 % of providers reported discussing cost with those
same patients [13]. In other surveys, over 40 % of physi-
cians reported that that they always or frequently dis-
cussed cost with their patients, and an additional 30 %
reported having these discussions sometimes or occasion-
ally [26, 27]. This contrasts with multiple patient surveys
which reported fewer than 20 % of patients discussing cost
with their physicians [14, 28, 29].
Cost conversation incidence in 1,755 clinic visits using three
definitions
When using the OoP Cost definition, 23 % of all visits in
our sample (95 % confidence interval [CI], 21 to 25)
contained a cost conversation. In the individual disease
settings, cost conversations were identified in 16 % of
breast oncology visits (95 % CI, 13 to 19), 30 % of de-
pression visits (95 % CI, 25 to 34), and 26 % of rheuma-
tology visits (95 % CI, 22 to 29; p < 0.001 for comparison
across the three settings; Fig. 2). More specifically, dollar
values were mentioned for the patient’s past, present, or
potential healthcare services (e.g. Dr: “The copay cost for
Humira was $400) in 5 % of breast cancer visits, and
10 % of rheumatoid arthritis and depression visits (P <
0.01 for comparison across the three clinical settings).
When using the Cost/Coverage definition, 30 % of all
clinic visits (95 % CI, 28 to 32) contained a cost conversa-
tion – 22 % of breast cancer visits (95 % CI, 19 to 25),
38 % of depression visits (95 % CI, 33 to 43), and 33 % of
rheumatoid arthritis visits (95 % CI, 30 to 37; p < 0.001 for
comparison across the three settings).
When using the Cost of Illness definition, 32 % of all
clinic visits (95 % CI, 30 to 34) contained a cost discus-
sion – 24 % of breast oncology visits (95 % CI, 21 to 27),
43 % of depression visits (95 % CI, 38 to 48), and 35 %
of rheumatology visits (95 % CI, 31 to 39, p < 0.001 for
overall comparison among the three settings).
Discussion
Estimates of physician-patient cost conversation incidence
vary substantially in the published literature [13, 15, 29, 39].
Differences in study design, clinical context, and mode
of inquiry (i.e. physician survey, patient survey, analysis
of recorded dialogue) contribute to this heterogeneity.
In this study, we found that variation in ‘cost conversa-
tion’ definition also impacts the estimated incidence of
physician-patient cost conversations. Specifically, we
Fig. 2 Estimated incidence of cost conversations using three different definitions. All visits featured adult patients (>18 years old) and
specialist physicians. *OoP Cost: discussion of the patient’s out-of-pocket costs for healthcare services; †Cost/Coverage: discussion of the
patient’s out-of-pocket costs OR insurance coverage; ‡Cost of Illness: any discussion of financial costs or insurance coverage broadly
related to health or healthcare [13–16, 18, 26–33, 38, 39, 44–46]
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observed significant differences between cost conversation
incidence estimates when using a definition limited to ex-
plicit discussions of the patient’s out-of-pocket costs for
healthcare services (OoP Cost), versus a definition that in-
cluded discussions of out-of-pocket costs or insurance
coverage (Cost/Coverage), versus a definition capturing all
discussions broadly related to the cost of health or health-
care (Cost of Illness). Importantly, the significant impact
of definition on incidence was observed in three different
clinical settings, using a mode of inquiry (analysis of nat-
urally occurring clinical dialogue), which allowed for rigor-
ous observation of the behavior in question.
Using the OoP Cost definition, the lowest rate of cost
conversation occurred in oncology clinics, where cost
conversations occurred in about 1 in 6 breast cancer
visits. Despite employing the strictest of the three defini-
tions, this estimate was still higher than some previous
survey estimates, which reported less than 1 in 6 breast
cancer patients ever discussed healthcare costs with their
physicians [14]. By contrast, the highest rate of cost con-
versation in our sample was in psychiatry clinics, where
nearly half of depression visits involved cost conversations
when using the Cost of Illness definition. This is note-
worthy because even when broadening the definition of
cost conversation to its most liberal interpretation, health-
care costs were not discussed in the majority of clinic
visits. Thus, our results may suggest that physician-patient
discussions about healthcare costs in outpatient settings
are not as rare as some prior surveys suggested [13, 29].
These findings have important clinical and policy impli-
cations. Approximately one third of Americans are bur-
dened by the costs of their medical care, either paying
their medical bills late or not paying them at all [1, 2].
Physician-patient cost conversations have been shown to
significantly increase the odds of patients receiving finan-
cial assistance, through avenues such as copay assistance
programs or switching to lower cost alternative therapies
[39, 40]. Additionally, 72 % of patients have reported that
discussing healthcare costs with their physicians was
helpful [16]. By supporting the notion that physician-
patient cost conversations are not altogether rare in
outpatient clinic visits, our findings may suggest that
such visits are promising sites for out-of-pocket cost
management. Indeed, in other analyses from these data,
44 % of physician-patient cost conversations included
discussion of cost saving strategies, further highlighting
the ongoing effort and potential for physician-patient
cost communication in the management of patients’
healthcare related financial burden [18].
Additionally, this study has implications for research
in the arena of physician-patient communication about
healthcare costs. We show that the incidence of cost
conversations varies significantly, depending on how re-
searchers define “cost conversation.” This finding
facilitates more meaningful synthesis and understanding
of the wide range of results from prior studies (Table 1).
This study also provides direction for future investigations
aiming to quantify the incidence, content, or impact of
cost conversations, as we provide a set of definitions that
can be transferred and utilized in future studies.
Notably, each of our definitions represents a potentially
valid conceptual construct of cost conversation, and is
suited to particular analytic aims. For example, when
evaluating the impact of cost conversations on patient ad-
herence, financial status, or medical outcomes, investiga-
tors may wish to focus on cost conversations specifically
about the patient’s costs, rather than costs to any stake-
holder; thus, the Cost/Coverage or OOP Cost definitions
would be preferred over the Cost of Illness definition.
Additionally, since insurance coverage may constitute an
important potential cost barrier for the patient, conversa-
tions about patient’s insurance coverage could also impact
patient adherence or outcomes, thus making the Cost/
Coverage definition a potentially optimal choice for this
particular research aim.
By contrast, when investigating the sociolinguistic as-
pects of cost communication, investigators may wish to
examine any conversation broadly related to cost. Since
discussion of costs borne by family or friends and rote
checks of insurance coverage are still, fundamentally,
communication about healthcare costs, the Cost of Ill-
ness definition may be best suited to these types of in-
vestigations. Lastly, if investigators seek to evaluate
physicians’ assessment of patients’ costs or the impact of
perceived high costs on treatment decisions, they may
wish to narrow their scope of cost conversation analysis
to those which include some description of the magni-
tude of the cost. In this case, the OoP Cost definition
may be best suited for the analysis in question.
One limitation of this study is the population sampled.
We focused on only three disease states, chosen because
they expose patients to high out-of-pocket costs [7, 29,
41–43]. These diseases represent varied contexts of a life-
threatening or terminal illness (breast cancer), a chronic
debilitating condition (rheumatoid arthritis), and a mental
health condition (depression), thereby offering greater
clinical diversity than many prior investigations on this
topic. But we cannot generalize our findings to other dis-
eases. Additionally, we did not measure cost conversation
incidence for all potential definitions of ‘cost conversation;
instead, we used a data-driven mixed-methods analysis to
create definitions that represented distinct and clinically
relevant cost conversation types. Thus, although not
an exhaustive inquiry of all potential definitions, our
study provides a helpful understanding of the impact
of key ‘cost conversation’ definitions and concepts on
estimates of cost conversation incidence. Further in-
vestigation will be needed to elucidate the complexity
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and nuance of physician-patient communication about
healthcare costs.
Conclusions
The frequency of physician-patient healthcare cost con-
versations has varied widely across studies [13, 15, 29, 39].
These reports have varied in part because the mode of
inquiry has varied, with lower rates reported from surveys
asking patients to recall frequency of cost discussion [13,
14, 29], and higher rates reported from analyses of actual
clinical dialogue [18, 32, 33]. In this study, we demonstrate
how much estimates can vary within the same mode of
inquiry. Importantly, our mode of analysis was naturally
occurring clinical dialogue, which allowed for rigorous ob-
servation of the behavior in question. Herein, we discov-
ered that estimates of cost conversation vary significantly
based on which of several possible definitions of cost con-
versation researchers adopt. This provides novel insights
for studies on this important aspect of patient experience.
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